Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 16/20 | 0.55 |
| ▸ | GRK3 | P35626 | 10/20 | 0.55 |
| ▸ | GRK5 | P34947 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539705 | 0.87 | GRK2 (0.56) | GRK2GRK3GRK5ROCK2 | |
| SCHEMBL5537464 | 0.86 | CYP17A1 (0.39) | GRK2GRK3GRK5MEN1KMT2A | |
| SCHEMBL5535879 | 0.86 | GRK2 (0.57) | GRK2GRK3GRK5MEN1KMT2A | |
| SCHEMBL5545993 | 0.83 | GRK2 (0.59) | GRK2GRK3ROCK2ROCK1 | |
| SCHEMBL5533048 | 0.82 | CA1 (0.57) | GRK2GRK3GRK5KMT2AROCK2 | |
| SCHEMBL5536140 | 0.82 | CYP17A1 (0.47) | GRK2GRK3GRK5MEN1KMT2A | |
| SCHEMBL5537408 | 0.78 | GRK2 (0.43) | GRK2GRK3GRK5MEN1KMT2A | |
| SCHEMBL5533006 | 0.77 | GRK2 (0.64) | GRK2 | |
| SCHEMBL5543418 | 0.72 | GRK2 (0.56) | GRK2GRK3GRK5MEN1KMT2A | |
| SCHEMBL28761689 | 0.72 | GRK2 (0.57) | GRK2GRK3GRK5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007008942-A2 | PHENYLAMINO-ACETIC ACID [1-(PYRIDIN-4-YL)-METHYLIDENE]-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | GRK2 2/4885GRK3 4/4885GRK5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.